Skip to main content
OpenTrials
Completed

NCT Number: NCT03476382

The Use of Bone Growth Stimulators for Osteoarthritis of the Knee.

The hypothesis of this study is that since osteoarthritis of the knee is primarily a bone disease where the joint changes are secondary, and bone growth stimulators function to decrease intraosseous venous congestion and remodel bone, then there is a potential benefit for the treatment of osteoarthritis of the knee with bone growth stimulators.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Coastal Carolinas Integrated Medicine

Supply, North Carolina, 28462, United States

About this study

The hypothesis of this study is based on the knowledge that osteoarthritis of the knee is primarily a bone disease, and the joint changes are secondary. Bone growth stimulators function to alleviate intraosseous venous congestion through the process of bone remodeling. The working hypothesis is that alleviation of intraosseous venous congestion leads to improved delivery of nutrition to the tissue to support the health of the bone with improvement in biomechanics leading to clinical improvement. Venous congestion is measured with intraosseous pressure. Additional objective evidence of biomarkers of bone metabolism as well as measurements of subjective questionnaires can provide evidence of benefit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must have diagnosis of osteoarthritis of the knee with radiographic evidence of joint space narrowing, Kellgren-Lawrence Classification grade Grade 3 or 4.
  • Subjects must discontinue corticosteroids administered by any route except intranasal spray, steroid- containing ophthalmic solutions and anti-asthmatics.
  • Subjects must speak English.
  • Subject must be willing and able to sign an informed consent document.
  • Subjects must be willing and able to comply with all study procedures for the duration of the clinical study.

Exclusion criteria

  • Subjects with a diagnosis of inflammatory arthritis such as rheumatoid arthritis, gout, joint infection, Lyme disease, or systemic lupus erythematosus.
  • Subjects with a diagnosis of secondary arthritis such as acromegaly, Charcot's arthropathy, hemochromatosis, or Wilson's disease.
  • Subjects who have had an injury to the index knee within 6 months of starting treatment.
  • Subjects must NOT have had arthroscopy within 8 weeks of starting treatment.
  • Subjects must NOT have had viscosupplementation within 8 weeks of starting treatment.
  • Subjects who plan to have surgery on the target knee within the study period.
  • Subjects with surgical metallic hardware in the target knee.
  • Subjects who are unwilling or unable to adhere to the follow up schedule and procedures.
  • Subjects who are pregnant.

Treatment and study plan

Ultrasound Bone Growth Stimulator

Device

Active device emits ultrasound signals.

Primary outcomes

  1. Intraosseous Venous Congestion measured by Intraossous Pressure.

    Time frame: 14 weeks

    Statistically significant decrease in intraosseous pressure following treatment.

Secondary outcomes

  1. Human Matrix Metalloproteinase-3 (MMP-3)

    Time frame: 14 weeks

    Statistically significant decrease in the biomarker MMP-3

  2. C- telopeptide.

    Time frame: 14 weeks

    Statistically significant decrease in the biomarker C- telopeptide.

  3. Change over time in WOMAC score.

    Time frame: 14 weeks

    The primary outcome variables are a statistically significant improvement in Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores.

Sponsors and collaborators

Lead sponsor

Coastal Carolinas Integrated Medicine

Other

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 26, 2018
Registry last updated
Jan 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.